STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 42, 2013, Pages 16975-16980

  Wang, Yuxin ^a,b   Van Boxel Dezaire, Anette H H ^b   Cheon, Hyeonjoo ^b   Yang, Jinbo ^a,b   Stark, George R ^b  

^a LANZHOU UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 6 RECEPTOR; ONCOSTATIN M; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STABLE EXPRESSION;

ANTINEOPLASTIC AGENTS; CYTOKINE RECEPTOR GP130; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-6; JANUS KINASE 1; JANUS KINASE 2; NEOPLASMS; ONCOSTATIN M; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84885712016     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1315862110     Document Type: Article

References (39)

1. Heinrich PC, et al. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1): 1-20.
2. Levy DE, Darnell JE, Jr. (2002) Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9): 651-662.
3. Croker BA, et al. (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4(6): 540-545.
4. Xia L, et al. (2002) Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 277(34): 30716-30723.
5. Kershaw NJ, et al. (2013) SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 20(4): 469-476.
6. Han W, Lo HW (2012) Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett 318(2): 124-134.
7. Leaman DW, et al. (1996) Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol Cell Biol 16(1): 369-375.
8. Downward J, Parker P, Waterfield MD (1984) Autophosphorylation sites on the epidermal growth factor receptor. Nature 311(5985): 483-485.
9. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Bio 1(1).
10. Gerwin N, Jia GQ, Kulbacki R, Gutierrez-Ramos JC (1995) Interleukin gene expression in mouse preimplantation development. Dev Immunol 4(3): 169-179.
11. Do DV, et al. (2013) A genetic and developmental pathway from STAT3 to the OCT4- NANOG circuit is essential for maintenance of ICM lineages in vivo. Genes Dev 27(12): 1378-1390.
12. Bhatt H, Brunet LJ, Stewart CL (1991) Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyst implantation. Proc Natl Acad Sci USA 88(24): 11408-11412.
13. Shen MM, Leder P (1992) Leukemia inhibitory factor is expressed by the preimplantation uterus and selectively blocks primitive ectoderm formation in vitro. Proc Natl Acad Sci USA 89(17): 8240-8244.
14. Stewart CL, et al. (1992) Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359(6390): 76-79.
15. Kopf M, et al. (1994) Impaired immune and acute-phase responses in interleukin-6- deficient mice. Nature 368(6469): 339-342.
16. Roberts AW, et al. (2001) Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 98(16): 9324-9329.
17. Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8(4): 945-954.
18. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9(11): 798-809.
19. Bromberg JF, et al. (1999) Stat3 as an oncogene. Cell 98(3): 295-303.
20. Ishihara K, Hirano T (2002) IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13(4-5): 357-368.
21. Hong DS, Angelo LS, Kurzrock R (2007) Interleukin-6 and its receptor in cancer: Implications for translational therapeutics. Cancer 110(9): 1911-1928.
22. McGeachy MJ, et al. (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8(12): 1390-1397.
23. Leu CM, Wong FH, Chang C, Huang SF, Hu CP (2003) Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22(49): 7809-7818.
24. Alberti C, et al. (2012) Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 31(37): 4139-4149.
25. Gao SP, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117(12): 3846-3856.
26. Wormald S, et al. (2006) The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J Biol Chem 281(16): 11135-11143.
27. Shao H, Cheng HY, Cook RG, Tweardy DJ (2003) Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63(14): 3923-3930.
28. Barnes TC, Anderson ME, Moots RJ (2011) The many faces of interleukin-6: The role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011: 721608.
29. Tamura T, Yanai H, Savitsky D, Taniguchi T (2008) The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26: 535-584.
30. Kano S, et al. (2008) The contribution of transcription factor IRF1 to the interferongamma- interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells. Nat Immunol 9(1): 34-41.
31. Mayer A, Denanglaire S, Viollet B, Leo O, Andris F (2008) AMP-activated protein kinase regulates lymphocyte responses to metabolic stress but is largely dispensable for immune cell development and function. Eur J Immunol 38(4): 948-956.
32. Bai A, et al. (2010) AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol 80(11): 1708-1717.
33. Mahner S, et al. (2008) C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99(8): 1269-1275.
34. Wang L, Sun Y, Jiang M, Zhang S, Wolfl S (2009) FOS proliferating network construction in early colorectal cancer (CRC) based on integrative significant function cluster and inferring analysis. Cancer Invest 27(8): 816-824.
35. Leith CP, et al. (1995) Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 86(6): 2329-2342.
36. Nakagawa M, et al. (1992) Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52(22): 6175-6181.
37. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE (2012) Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 15(1-2): 50-61.
38. Zhang X, Xiao W, Wang L, Tian Z, Zhang J (2011) Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS ONE 6(6):e20965.
39. Sen M, et al. (2012) Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 18(18): 4986-4996.